Wall Street analysts’ mean price target for Seaport Therapeutics (SPTX) implies 77.9% upside from current levels. Zacks notes that while consensus price targets have not proven reliably effective, strong agreement among analysts in raising earnings estimates signals potential upside in the stock.
Wall Street Analysts See 77.9% Upside in Seaport Therapeutics (SPTX), Zacks Reports
The mean of analysts’ price targets for Seaport Therapeutics, Inc. (SPTX) points to a 77.9% upside in the stock, according to a Zacks report published Thursday.
Consensus Target and Its Limits
Zacks noted that the consensus price target is a highly sought-after metric among investors. However, the report also stated that this measure “has not proven reasonably effective” as a predictor of actual stock performance.
Earnings Estimate Revisions Cited as Signal
Beyond the price target, Zacks pointed to analyst behavior on earnings estimates as a separate indicator. According to the report, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Key Takeaways
- The mean analyst price target for SPTX implies 77.9% upside from current levels.
- Zacks cautioned that consensus price targets have not proven reasonably effective.
- The report cited strong agreement among analysts raising earnings estimates as a signal of potential upside.